Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

被引：0
|
作者：
Leiming Xia
Wanlu Tian
Yiming Zhao
Lingling Jiang
Wei Qian
Lei Jiang
Ling Ge
Jianjun Li
Fengbo Jin
Mingzhen Yang
机构：
[1] the first affiliated hospital of Anhui Medical University,Department of Hematology
[2] Anhui Public Health Clinical Center,undefined
[3] Anhui Provincial Institute of Translational Medicine,undefined
来源：
Signal Transduction and Targeted Therapy | / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Xia, Leiming
    Tian, Wanlu
    Zhao, Yiming
    Jiang, Lingling
    Qian, Wei
    Jiang, Lei
    Ge, Ling
    Li, Jianjun
    Jin, Fengbo
    Yang, Mingzhen
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [2] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
  • [3] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy (vol 52, pg 29, 2022)
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (05) : 456 - 456
  • [4] Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations
    Konopleva, Marina
    Thirman, Michael
    Pratz, Keith W.
    Letai, Anthony G.
    Recher, Christian
    Pullarkat, Vinod A.
    Kantarjian, Hagop M.
    Dail, Monique
    Duan, Yinghui
    Chyla, Brenda J.
    Potluri, Jalaja
    Miller, Catherine
    Dinardo, Courtney D.
    Wei, Andrew H.
    BLOOD, 2020, 136
  • [5] Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations
    Pollyea, Daniel A.
    Dinardo, Courtney D.
    Arellano, Martha L.
    Pigneux, Arnaud
    Fiedler, Walter
    Konopleva, Marina
    Rizzieri, David A.
    Smith, B. Douglas
    Shinagawa, Atsushi
    Lemoli, Roberto M.
    Dail, Monique
    Duan, Yinghui
    Chyla, Brenda J.
    Potluri, Jalaja
    Ridgeway, Jean A.
    Kantarjian, Hagop M.
    BLOOD, 2020, 136
  • [6] A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)
    Daver, Naval
    Liu, Ke
    Werneke, Scott
    Rustia, Evelyn
    Ramsingh, Giri
    Vyas, Paresh
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S5 - S5
  • [7] Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
    DiNardo, C. D.
    Jonas, B. A.
    Pullarkat, V.
    Thirman, M. J.
    Garcia, J. S.
    Wei, A. H.
    Konopleva, M.
    Doehner, H.
    Letai, A.
    Fenaux, P.
    Koller, E.
    Havelange, V.
    Leber, B.
    Esteve, J.
    Wang, J.
    Pejsa, V.
    Hajek, R.
    Porkka, K.
    Illes, A.
    Lavie, D.
    Lemoli, R. M.
    Yamamoto, K.
    Yoon, S. -S.
    Jang, J. -H.
    Yeh, S. -P.
    Turgut, M.
    Hong, W. -J.
    Zhou, Y.
    Potluri, J.
    Pratz, K. W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07): : 617 - 629
  • [8] A Phase III, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy (ENHANCE-3)
    Daver, Naval G.
    Liu, Ke
    Kuwahara, Sowmya B.
    Caldwell, Kenneth
    Vyas, Paresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S313 - S314
  • [9] Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy
    Taenaka, Ryutaro
    Obara, Teppei
    Kohno, Kentaro
    Aoki, Kenichi
    Ogawa, Ryosuke
    INTERNAL MEDICINE, 2023, 62 (05) : 689 - 695
  • [10] Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
    Richard-Carpentier, Guillaume
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
12345